首页> 外文OA文献 >Staging and tumor biological mechanisms of lymph node metastasis in invasive urinary bladder cancer
【2h】

Staging and tumor biological mechanisms of lymph node metastasis in invasive urinary bladder cancer

机译:浸润性膀胱癌淋巴结转移的分期及其肿瘤生物学机制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Aim: To study the possibility of detecting lymph node metastasis in locally advanced urinary bladder cancer (UBC) treated with radical cystectomy (RC) by using preoperative positron emission tomography/computed tomography (PET/CT) and peroperative sentinel node biopsy (SNB) technique. We also investigate the clinical significance of macrophage traits expression by cancer cells, M2-macrophage infiltration (MI) in tumor stroma and the immunohistochemical expression of biomarkers in cancer cells in relation to clinicopathologic data. Patients and Methods: We studied prospectively 122 patients with UBC, pathological stage pT1–pT4 treated with RC and pelvic lymph node dissection (PLND) during 2005–2011 at the Department of Urology, Linköping University Hospital. In the first study, we compared the results of preoperative PET/CT and conventional CT with the findings of postoperative histopathological evaluation of lymph nodes (LNs). In the second study we investigated the value of SNB technique for detecting pathological LNs during RC in patients with UBC. W also examined the significance of the primary tumor location in the bladder in predicting the site of LN metastases, and the prognostic significance of lympho-vascular invasion (LVI) and lymph node metastasis density (LNMD) on survival. In the third study, we investigate the clinical significance of macrophage infiltration (MI) in tumor stroma and macrophage-traits expression by tumor cells. In the fourth study, we investigate the cell cycle suppression proteins p53, p21, pRb, p16, p14 ARF as well as tumors proliferative protein Ki67 and DNA repair protein ERCC1 expression in cancer cells. The results were compared with clinical and pathological characteristics and outcome. Results: Prior to RC, PET/CT was used to detect LN metastasis in 54 patients. PET/CT had 41% sensitivity, 86% specificity, 58% PPV, and 76% NPV, whereas the corresponding figures for conventional CT were 41%, 89%, 64%, and 77%. SNB was performed during RC in 103 patients. A median number of 29 (range 7–68) nodes per patient were examined. SNs were detected in 83 out of 103 patients (81%). The sensitivity and specificity for detecting metastatic disease by SNB varied among LN stations, with average values of 67% -90%. LNMD or ≥8% and LVI were significantly related to shorter survival. In 103 patients, MI was high in 33% of cases, while moderate and low infiltration occurred in 42% and 25% of tumors respectively. Patients with tumors containing high and moderate compared to low MI had low rate of LN metastases (P=0.06) and improved survival (P=0.06), although not at significant level. The expression of different tumor suppression proteins was altered in 47-91% of the patients. There were no significant association between cancer specific survival (CSS) and any of the studied biomarkers. In case of altered p14ARF, ERCC1 or p21, CSS was low in case of low p53 immunostaining but increased in case of p53 accumulation, although not at a significant level, indicating a possible protective effect of p53 accumulation in these cases. Conclusion: PET/ CT provided no improvement over conventional CT in detection and localization of regional LN metastases in bladder cancer. It is possible to detect the SN but the technique is not a reliable for perioperative localization of LN metastases; however, LVI and LNMD at a cut-off level of 8% had significant prognostic values. MI in the tumor microenvironment but not CD163 expression in tumor cells seems to be synergistic with the immune response against urinary bladder cancer. Our results further indicate that altered p53 might have protective effect on survival in case of altered p14ARF, p21, or ERCC1 indicating an interaction between these biomarkers.
机译:目的:通过术前正电子发射断层扫描/计算机断层扫描(PET / CT)和术前哨兵淋巴结活检(SNB)技术,研究在根治性膀胱切除术(RC)治疗的局部晚期膀胱癌(UBC)中检测淋巴结转移的可能性。我们还研究与临床病理数据相关的癌细胞巨噬细胞性状表达,肿瘤基质中M2-巨噬细胞浸润(MI)以及癌细胞中生物标志物的免疫组织化学表达的临床意义。患者和方法:我们于2005-2011年在林雪平大学医院泌尿外科对122例UBC,病理分期为pT1-pT4的RC和盆腔淋巴结清扫术(PLND)进行了研究。在第一项研究中,我们将术前PET / CT和常规CT的结果与术后淋巴结(LNs)的组织病理学评估的结果进行了比较。在第二项研究中,我们调查了SNB技术在UBC患者RC期间检测病理LN的价值。 W还检查了膀胱原发肿瘤位置在预测LN转移部位中的意义,以及淋巴管浸润(LVI)和淋巴结转移密度(LNMD)对生存的预后意义。在第三项研究中,我们调查了巨噬细胞浸润(MI)在肿瘤基质和肿瘤细胞表达巨噬细胞特性中的临床意义。在第四项研究中,我们研究了细胞周期抑制蛋白p53,p21,pRb,p16,p14 ARF以及肿瘤增殖蛋白Ki67和DNA修复蛋白ERCC1在癌细胞中的表达。将结果与临床和病理学特征及结果进行比较。结果:在进行RC之前,PET / CT被用于检测54例患者的LN转移。 PET / CT的敏感性为41%,特异性为86%,PPV为58%,NPV为76%,而常规CT的相应数字分别为41%,89%,64%和77%。在RC期间对103例患者进行了SNB。每位患者检查了29个淋巴结中位数(7-68个)。 103例患者中有83例(81%)检测到SN。 LN站对SNB检测转移性疾病的敏感性和特异性各不相同,平均值为67%-90%。 LNMD或≥8%和LVI与生存期缩短显着相关。在103例患者中,MI占33%的病例较高,而中度和低浸润分别发生在42%和25%的肿瘤中。与低心肌梗死相比,高,中度肿瘤患者的LN转移率低(P = 0.06),生存率提高(P = 0.06),尽管水平不高。 47-91%的患者改变了不同的抑癌蛋白表达。癌症特异性生存率(CSS)与任何已研究的生物标志物之间均无显着关联。如果p14ARF,ERCC1或p21发生改变,则在p53免疫染色低的情况下CSS较低,而在p53积累的情况下CSS升高,尽管水平不高,但表明在这些情况下p53积累可能具有保护作用。结论:在膀胱癌区域性LN转移的检测和定位方面,PET / CT与常规CT相比没有任何改善。可以检测到SN,但该技术对于LN转移的围手术期定位并不可靠;但是,LVI和LNMD的临界水平为8%时,其预后价值显着。肿瘤微环境中的MI,而不是肿瘤细胞中的CD163表达,似乎与针对膀胱癌的免疫反应具有协同作用。我们的结果进一步表明,在p14ARF,p21或ERCC1发生变化的情况下,发生变化的p53可能对生存具有保护作用,表明这些生物标志物之间存在相互作用。

著录项

  • 作者

    Aljabery, Firas;

  • 作者单位
  • 年度 2017
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号